orlistat 60 mg
Drug1 tablet 3 times a day
NCT Number: NCT01755676
The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Centro de Medicina Reprodutiva Dr Carlos Isaia Filho, Porto Alegre, Rio Grande do Sul, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 tablet 3 times a day
1 tablet 3 times a day
Time frame: 112 days
Time frame: 112 days
EMS
Industry
A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg as Adjuvant Treatment of Obesity in Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04021355
Body Weight, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial DetailsNCT06752967
Behavior, Body Weight
Herlev, Denmark
View Trial DetailsNCT06254183
Acute Kidney Injury, Body Weight
Al Mansurah, Egypt
View Trial Details